195 related articles for article (PubMed ID: 31297836)
21. Inactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination.
Santa Maria F; Laughhunn A; Lanteri MC; Aubry M; Musso D; Stassinopoulos A
Transfusion; 2017 Aug; 57(8):2016-2025. PubMed ID: 28671343
[TBL] [Abstract][Full Text] [Related]
22. Efficient inactivation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in human apheresis platelet concentrates with amotosalen and ultraviolet A light.
Hindawi SI; El-Kafrawy SA; Hassan AM; Badawi MA; Bayoumi MM; Almalki AA; Zowawi HM; Tolah AM; Alandijany TA; Abunada Q; Picard-Maureau M; Damanhouri GA; Azhar EI
Transfus Clin Biol; 2022 Feb; 29(1):31-36. PubMed ID: 34411748
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and functional characteristics of stored (double-dose) buffy-coat platelet concentrates treated with amotosalen and a prototype UVA light-emitting diode illuminator.
Brouard N; Pissenem-Rudwill F; Mouriaux C; Haas D; Galvanin A; Kientz D; Mangin PH; Isola H; Hechler B
Transfusion; 2023 Oct; 63(10):1937-1950. PubMed ID: 37615493
[TBL] [Abstract][Full Text] [Related]
24. Assessment of dengue virus inactivation in random donor platelets using amotosalen and ultraviolet A illumination.
Kumar A; Tiwari AK; Kumar S; Biswas A; Singh G; Chatterjee K; Chakroborty S; Sunil S
Asian J Transfus Sci; 2022; 16(1):67-72. PubMed ID: 36199414
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.
Lanteri MC; Santa-Maria F; Laughhunn A; Girard YA; Picard-Maureau M; Payrat JM; Irsch J; Stassinopoulos A; Bringmann P
Transfusion; 2020 Jun; 60(6):1319-1331. PubMed ID: 32333396
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model.
Slichter SJ; Fish D; Abrams VK; Gaur L; Nelson K; Bolgiano D
Blood; 2005 Jan; 105(2):847-54. PubMed ID: 15231575
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light.
Lin L; Hanson CV; Alter HJ; Jauvin V; Bernard KA; Murthy KK; Metzel P; Corash L
Transfusion; 2005 Apr; 45(4):580-90. PubMed ID: 15819680
[TBL] [Abstract][Full Text] [Related]
28. Bacterial contamination of platelets for transfusion: strategies for prevention.
Levy JH; Neal MD; Herman JH
Crit Care; 2018 Oct; 22(1):271. PubMed ID: 30367640
[TBL] [Abstract][Full Text] [Related]
29. Experimental animal model of refractoriness to donor platelets: the effect of plasma removal and the extent of white cell reduction on allogeneic alloimmunization.
Bordin JO; Bardossy L; Blajchman MA
Transfusion; 1993 Oct; 33(10):798-801. PubMed ID: 8236419
[TBL] [Abstract][Full Text] [Related]
30. Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events.
Hamzeh-Cognasse H; Laradi S; Osselaer JC; Cognasse F; Garraud O
Vox Sang; 2015 Feb; 108(2):205-7. PubMed ID: 25334045
[TBL] [Abstract][Full Text] [Related]
31. Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
Stivala S; Gobbato S; Infanti L; Reiner MF; Bonetti N; Meyer SC; Camici GG; Lüscher TF; Buser A; Beer JH
Haematologica; 2017 Oct; 102(10):1650-1660. PubMed ID: 28729303
[TBL] [Abstract][Full Text] [Related]
32. Investigation of bacterial inactivation in apheresis platelets with 24 or 30 hours between inoculation and inactivation.
Wagner SJ; Benjamin RJ; Hapip CA; Kaelber NS; Turgeon AM; Skripchenko A; Stassinopoulos A
Vox Sang; 2016 Oct; 111(3):226-234. PubMed ID: 27185478
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the enzyme purine nucleoside phosphorylase (PNP) reduces refractoriness to transfused platelets in a dog model.
Slichter SJ; Deeg HJ; Osborne WR
Br J Haematol; 1990 Aug; 75(4):591-7. PubMed ID: 2119794
[TBL] [Abstract][Full Text] [Related]
34. Transfusion of pathogen-reduced platelet components without leukoreduction.
Sim J; Tsoi WC; Lee CK; Leung R; Lam CCK; Koontz C; Liu AY; Huang N; Benjamin RJ; Vermeij HJ; Stassinopoulos A; Corash L; Lie AKW
Transfusion; 2019 Jun; 59(6):1953-1961. PubMed ID: 30919465
[TBL] [Abstract][Full Text] [Related]
35. Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma.
Azhar EI; Hindawi SI; El-Kafrawy SA; Hassan AM; Tolah AM; Alandijany TA; Bajrai LH; Damanhouri GA
Vox Sang; 2021 Jul; 116(6):673-681. PubMed ID: 33277935
[TBL] [Abstract][Full Text] [Related]
36. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV.
Van Voorhis WC; Barrett LK; Eastman RT; Alfonso R; Dupuis K
Antimicrob Agents Chemother; 2003 Feb; 47(2):475-9. PubMed ID: 12543646
[TBL] [Abstract][Full Text] [Related]
37. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
Trial to Reduce Alloimmunization to Platelets Study Group
N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
[TBL] [Abstract][Full Text] [Related]
38. Haemostatic responsiveness and release of biological response modifiers following cryopreservation of platelets treated with amotosalen and ultraviolet A light.
Tynngård N; Wikman A; Uhlin M; Sandgren P
Blood Transfus; 2020 May; 18(3):191-199. PubMed ID: 31403931
[TBL] [Abstract][Full Text] [Related]
39. Assessment of nucleic acid modification induced by amotosalen and ultraviolet A light treatment of platelets and plasma using real-time polymerase chain reaction amplification of variable length fragments of mitochondrial DNA.
Bakkour S; Chafets DM; Wen L; Dupuis K; Castro G; Green JM; Stassinopoulos A; Busch MP; Lee TH
Transfusion; 2016 Feb; 56(2):410-20. PubMed ID: 26446053
[TBL] [Abstract][Full Text] [Related]
40. Approaches to preventing or reversing platelet alloimmunization using animal models.
Slichter SJ; Weiden PL; Kane PJ; Storb RF
Transfusion; 1988; 28(2):103-8. PubMed ID: 3354038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
